Study ID (Trial registration) | Study design | Number randomized | Age of included women | Trial arms | Duration of treatment (months) | Outcomes reported | Country |
---|---|---|---|---|---|---|---|
Burke 2018 NCT02293694 | Open-label, parallel group, randomized clinical trial | 731 | 18–40 | Participants were randomized in a 1:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg | 12 | Continuation, satisfaction, failure (unintended pregnancy), side effects | Malawi |
Kohn 2018 NCT02509767 | Multicenter, open label, randomized parallel group clinical trial | 401 | 15–44 | Participants were randomized in a 1:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg | 12 | Continuation, satisfaction, failure (unintended pregnancy), side effects | USA |
Beasley 2014 NCT01019369 | Open label, parallel group, randomized clinical trial | 132 | 18 or greater | Participants were randomized in a 2:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg | 12 | Continuation, satisfaction, side effects | USA |